Alcoholism and depression: a placebo controlled study with viloxazine.

Abstract	Depressive disorders are frequently associated with alcohol abuse. Though many studies have been carried out to clarify the role of antidepressant drugs in the management of alcoholic patients, the data are controversial. The present placebo-controlled study was planned to assess the antidepressant and attenuating drinking-behaviour efficacy of viloxazine (400 mg per os daily) versus a placebo in 30 dysthymic patients affected by alcohol dependence. The results significantly favour viloxazine treatment in alleviating depression and in reducing alcohol abuse. All patients showed baseline haematochemical evidence of liver dysfunction that did not change significantly during the treatment.
Authors	A C Altamura, M C Mauri, T Girardi, B Panetta
Journal	International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 10 Issue 5 Pg. 293-8 ( 1990) ISSN: 0251-1649 [Print] Switzerland
PMID	2079386 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Viloxazine
Topics	Adult Alcohol Drinking Alcoholism (complications, drug therapy, psychology) Depressive Disorder (complications, drug therapy, psychology) Double-Blind Method Female Humans Male Middle Aged Psychiatric Status Rating Scales Viloxazine (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!